Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation

Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation

All the spike proteins from BA.4/5 sublineages, and those of BA.4/5 carrying point mutations of R346S and N658S, showed similar binding affinities to ACE2, with dissociation constant values ranging 0·39–0·49 nM. [...]the expansion of BA.4.6 cannot be explained by a higher affinity for human ACE2. Ne...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases Vol. 22; no. 12; pp. 1666 - 1668
Main Authors: Wang, Qian, Li, Zhiteng, Ho, Jerren, Guo, Yicheng, Yeh, Andre Yanchen, Mohri, Hiroshi, Liu, Michael, Wang, Maple, Yu, Jian, Shah, Jayesh G, Chang, Jennifer Y, Herbas, Favio, Yin, Michael T, Sobieszczyk, Magdalena E, Sheng, Zizhang, Liu, Lihong, Ho, David D
Format: Journal Article
Language:English
Published: United States Elsevier Ltd 01-12-2022
Elsevier Limited
Subjects:
ACE2
Affinity
Angiotensin-converting enzyme 2
Antibodies
Antibodies, Viral
Coronaviruses
Correspondence
COVID-19
Disease transmission
Humans
Immunoglobulins
Infectious diseases
Inventors
Monoclonal antibodies
mRNA
Mutation
Pandemics
Patent applications
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Vaccination
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:All the spike proteins from BA.4/5 sublineages, and those of BA.4/5 carrying point mutations of R346S and N658S, showed similar binding affinities to ACE2, with dissociation constant values ranging 0·39–0·49 nM. [...]the expansion of BA.4.6 cannot be explained by a higher affinity for human ACE2. Next, to investigate the antibody evasion properties of BA.4.6, BA.4.7, BA.5.9, and BF.7, we assessed the sensitivity of their corresponding pseudoviruses to neutralisation with serum samples from healthy individuals who had received three doses of a COVID-19 mRNA vaccine BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna; ie, who had received booster doses) and patients with either BA.1, BA.2, or BA.4/5 breakthrough infection after vaccination (figure; appendix p 1). JY, LL, and DDH are inventors on patent applications (WO2021236998) or provisional patent applications (63/271,627) filed by Columbia University for a number of SARS-CoV-2 neutralising antibodies described in this Correspondence; both sets of applications are under review.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(22)00694-6